Pathophysiology of cardiorenal syndrome

Česká verzia

Authors: F. Málek
Published in the journal: Kardiol Rev Int Med 2012, 14(4): 233-236
Category:

Summary

Cardiorenal syndrome is defined as a state, when each dysfunctional organ – heart or kidney – has the ability to initiate and perpetuate disease in the other organ through common hemodynamic, neurohormonal, immunological and biochemical feedback pathways. In the pathophysiology of cardiorenal syndrome, several factors play role: decreased cardiac output associated with increased renal vein and intrabdominal pressure, lack of renin-angiotensin-aldosteron system inhibition, renal sympathetic nerve activation in arteries, oxidative stress, anemia and erythropoetin underproduction and others.

Keywords:
cardiorenal syndrome – heart failure – renal dysfunction – patophysiology

Zdroje

1. Bock JS, Gottlieb SS. Cardiorenal Syndrome: New Perspectives. Circulation 2010; 121: 2592–2660.

2. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957–962.

3. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31: 1402–1415.

4. Bongartz LG, Cramer MJ, Doevendans PA et al. The severe cardiorenal syndrome: ‚Guyton revisited‘. Eur Heart J 2005; 26: 11–17.

5. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrom. Circulation 2004; 110: 1514–1517.

6. McAlister FA, Ezekowitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004–1009.

7. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203–210.

8. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (Suppl 12): S16–S23.

9. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41 (5 Suppl): 11–17.

10. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402–1407.

11. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364–1372.

12. Sarnak MJ, Levey AS, Schoolwerth AC et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169.

13. Best PJ, Lennon R, Ting HH et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113–1119.

14. Rao V, Weisel RD, Buth KJ et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation 1997; 96 (9 Suppl): II38–II45

15. Gibson CM, Pinto DS, Murphy SA et al. TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535–1543.

16. Jungers P, Qualim Z, Nguyen-Khoa T et al. Cardioprotection: an essential component for predialysis chronic renal failure treatment. Nephrologie 2003; 24: 79–88.

17. Nohria A, Hasselblad V, Stebbins A et al. Cardiorenal interactions: insights frome the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268–1274.

18. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138: 285–290.

19. Mullens W, Abrahams T, Skouri HN et al. Elevated intra-abdominal pressure in acute decomensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008; 51: 300–306.

20. Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589–296.

21. Malbrain ML, Cheatham ML, Kirkpatrick SM et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med 2006; 32: 1722–1732.

22. Krum H, Schlaich M, Whitbourn R et al. Catheter--based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275–1281.

23. McKelvie RS, Moe GW, Cheung A et al. The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Paliative Care. Can J Cardiol 2011; 27: 319–338.

24. Esler M, Jennings G, Korner P et al. Assessment of human sympathetic nervous system activity from measurments of norepinephrine turnover. Hypertension 1988; 11: 3–20.

25. Petersson M, Friberg P, Eisenhofer G et al. Long--term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005; 26: 906–913.

26. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932–934.

27. Brandt MC, Mahfoud F, Reda S et al. Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension. J Am Coll Cardiol 2012; 59: 901–909.

28. Schmieder RE, Redon J, Grasso G et al. ESH Position Paper: Renal Denervation – an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837–841.

29. Widimský P, Filipovský J, Widimský J Jr et al. Odborné stanovisko České kardiologické společnosti a České společnosti pro hypertenzi k provádění katetrizačních renálních denervací (RDN) v České republice. Cor Vasa 2012; 54: 155–159.

30. Neužil P, Reddy VY, Schejbalová M et al. Katetrizační ablace renálního sympatiku u nemocných s rezistentní formou arteriální hypertenze. Interv Akut Kardiol 2012; 11: 48–51.

31. Remuzzi G, Perico N, Mancia M et al. The role of the renin-angiotensin-aldosteron system in the progression of chronic kidney dinase. Kidney Int 2005; Suppl: S57–S65.

32. Tojo A, Onozato ML, Kobayashi N et al. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002; 40: 834–839.

33. Jie KE, Verhaar MC, Cramer MJ et al. Erythropoetin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal conectors. Am J Physiol Renal Physiol 2006; 291: F932–944.

34. Kostam MA. Gheorghiade M, Burnett JC Jr et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patiens hospitalized for worsening heart failure: the EVEREST Otucome Trial. JAMA 2007; 297: 1319–1331.

35. Funaya H, Kitakaze M, Node K et al. Plasma adenosine levels increase in patiens with chronic heart failure. Circulation 1997; 95: 1348–1353.